Trials / Recruiting
RecruitingNCT07375355
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Explore the Effectiveness and Safety of Scemblix (Asciminib) for Newly Diagnosed CML-CP Patients in China Real World Setting (ASC4CN)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.
Conditions
Timeline
- Start date
- 2026-02-12
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2026-01-29
- Last updated
- 2026-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07375355. Inclusion in this directory is not an endorsement.